4,901 trials
Healthy Volunteers
Primary: Change From Baseline in Electrocardiogram Results (QTcNi) at Time of Maximum Plasma Concentration (Tmax) on Day 1 — -3.37; 12.96; -0.94; -0.91 msec
Infections, Papillomavirus
Primary: Number of Subjects Reporting Serious Adverse Events — 1 Participants
Dyslipidemia
Primary: Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid — 116; 121 μg·hr/mL
Colorectal Neoplasms · Neoplasms
Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 9; 5; 12 participants
Healthy
Primary: Maximal Plasma Concentration (Cmax) — 2,503.04; 2,496.88; 1,706.03 pg/mL
Actinic Keratosis
Primary: Number of Participants With 100% Clearance of Actinic Keratosis Lesions: Comparison of Taro Imiquimod 5% and Aldara-Imiquimod 5% — 63; 54 Participants
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Rosiglitazone — 0.41; 0.43 ug/mL
Dyslipidemia
Primary: Maximum Plasma Concentration (Cmax) of Nicotinuric Acid — 1190; 1260 ng/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 6.84 ng/mL
Pharmacokinetics
Primary: Maximum Serum Concentration (Cmax) — 2450.15; 3553.15 pg/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration — 6192.77 picograms/ml
Healthy
Primary: Area Under the Plasma Drug Concentration-time Curve From Time 0 to Infinity (AUC) — 1308; 1326 microgram *day/mL
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC — 45.04; 28.66; 46.34; 29.97 ng/ml
Pain
Primary: Plasma Area Under the Curve (AUC(0 to Infinity)) for Etoricoxib — 32.65; 33.28 µg times hr/mL
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 3,569.47; 10,708.40; 11,014.93; 11,202.87 ng/mL